Many reports indicate that ATR-CHK1 activation may promote tumor growth and that CHEK1 expression is upregulated in triple-negative breast cancer, neuroblastoma, T-cell leukemia, nasopharyngeal cancer, ovarian cancer, and glioblastoma [28,29,30,31,32,33]. This evidence concerns the gene CHEK1 and nasopharyngeal carcinoma.